Cargando…
The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascu...
Autores principales: | Atmowihardjo, Leila, Schippers, Job R., Bartelink, Imke H., Bet, Pierre M., van Rein, Nienke, Purdy, Keith, Cavalla, David, Comberiati, Valérie, McElroy, Andrew, Snape, Sue D., Bogaard, Harm Jan, Heunks, Leo, Juffermans, Nicole, Schultz, Marcus, Tuinman, Pieter R., Bos, Lieuwe D. J., Aman, Jurjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848942/ https://www.ncbi.nlm.nih.gov/pubmed/35172891 http://dx.doi.org/10.1186/s13063-022-06055-9 |
Ejemplares similares
-
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial
por: Atmowihardjo, Leila N., et al.
Publicado: (2023) -
The diagnostic accuracy of lung ultrasound to determine PiCCO-derived extravascular lung water in invasively ventilated patients with COVID-19 ARDS
por: Atmowihardjo, Leila N., et al.
Publicado: (2023) -
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study
por: Bartelink, Imke H., et al.
Publicado: (2021) -
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19
por: Baalbaki, Nadia, et al.
Publicado: (2023) -
Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)